Psychiatric comorbidities significantly impair health outcomes in individuals with chronic neurological conditions. Among these complications, psychosis in epilepsy represents one of the most debilitating yet underdiagnosed challenges in clinical neuro-psychiatry. Historically, clinicians estimated that psychotic symptoms afflicted approximately five to seven percent of this clinical population. However, recent multicenter data indicate that the true burden is substantially higher. A robust retrospective cohort study conducted across three tertiary epilepsy centers in West China evaluated 882 patients to assess prevalence, phenomenological patterns, and predictive markers. Consequently, researchers identified psychosis of epilepsy in 13% of participants, underscoring an urgent need for heightened diagnostic vigilance. Because psychiatric symptoms frequently compound seizure-related disability, clinicians must understand the complex neurobiological links between abnormal electrical activity and behavioral dysregulation.

Epidemiological Insights: Prevalence of Psychosis in Epilepsy

The multicenter investigation demonstrated that 112 out of 882 patients met formal criteria for psychosis of epilepsy, translating to an overall prevalence of 13%. This observed rate nearly doubles the estimates reported in historical literature. In addition to patients whose psychiatric symptoms developed secondary to recurrent seizures, 27 individuals (approximately 3%) presented with psychosis prior to their initial epilepsy diagnosis. Therefore, the bidirectional relationship between psychotic disorders and seizure vulnerability warrants careful clinical observation. When investigators stratified the affected cohort by temporal manifestation, interictal psychosis emerged as the most prevalent subtype, occurring in 7% of the total cohort. Meanwhile, ictal psychosis developed in 3% of patients, and postictal psychosis appeared in 2%. These robust findings indicate that neuropsychiatric vulnerability is pervasive across diverse seizure syndromes. Consequently, tertiary care providers must establish routine psychiatric surveillance protocols to identify vulnerable patients before severe behavioral symptoms manifest.

Differentiating Interictal, Ictal, and Postictal Subtypes

Clinicians classify psychosis associated with seizure disorders into three distinct chronobiological categories. Interictal psychosis occurs independently of acute seizure episodes, persisting during periods of normal electroencephalographic baseline activity. Patients experiencing this subtype often display chronic paranoid delusions, hallucinations, and substantial emotional blunting. In contrast, ictal psychosis develops directly during abnormal paroxysmal discharges, frequently manifesting as nonconvulsive status epilepticus with confusion, automatisms, and transient hallucinations. Furthermore, postictal psychosis arises typically after a characteristic lucid interval lasting 12 to 72 hours following a seizure cluster. During these postictal episodes, patients frequently exhibit intense affective symptoms, psychomotor agitation, and rapid fluctuations in reality testing. Because each subtype features unique pathophysiological mechanisms and distinct temporal profiles, accurate classification remains paramount. Neurologists and psychiatrists must collaborate closely to ensure that acute postictal behavioral changes are not erroneously misdiagnosed as chronic schizophreniform disorders.

Symptom Profiles: Psychosis of Epilepsy Versus Pre-Epilepsy Psychosis

The phenotypic expression of psychosis differs markedly depending on whether psychiatric illness precedes or follows the onset of epilepsy. In the multicenter cohort, individuals with psychosis diagnosed prior to epilepsy exhibited less frequent seizures, a lower proportion of drug-resistant epilepsy, and reduced overall seizure severity. However, these pre-epilepsy psychosis patients suffered from significantly higher frequencies and severity of complex hallucinations and persecutory delusions. Conversely, patients who developed psychosis secondary to epilepsy presented with a distinct clinical profile. In this group, negative and behavioral symptoms predominated over florid auditory hallucinations. Specifically, bizarre behavior, avolition, and anhedonia represented the three most prevalent psychotic manifestations observed in validated psychiatric assessments. Consequently, clinicians should not rely solely on positive psychotic features when screening epilepsy cohorts. Recognizing avolition and affective withdrawal as core indicators of psychosis of epilepsy ensures timely psychiatric intervention and prevents progressive psychosocial deterioration.

Key Neurological and Pharmacological Risk Factors

Multivariable risk modeling reveals distinct clinical and pharmacological determinants across psychotic subtypes. For interictal psychosis, significant predictors include an earlier age at seizure onset, a confirmed family history of schizophrenia, and active, frequent seizures. In addition, neuroimaging markers such as temporal lobe epilepsy and hippocampal sclerosis substantially elevate susceptibility. These structural changes disrupt limbic circuitry, which impairs emotional regulation and reality testing. Furthermore, pharmacological factors strongly influence vulnerability. Specifically, therapy with two or more antiseizure medications and the clinical use of perampanel significantly correlate with interictal psychosis. Perampanel, a selective non-competitive AMPA receptor antagonist, carries recognized risks for irritability, hostility, and psychiatric decompensation. Meanwhile, severe head trauma, frequent active seizures, and temporal lobe epilepsy independently predict postictal psychosis. In contrast, active seizure frequency alone predicts ictal psychosis, emphasizing the direct role of uncontrolled paroxysmal discharges in driving acute episodic psychosis.

Clinical Implications for Multidisciplinary Patient Management

The high prevalence and severe burden of psychotic symptoms in epilepsy necessitate a coordinated multidisciplinary care model. Because polytherapy and specific agents like perampanel increase psychiatric vulnerability, clinicians must review medication regimens meticulously. When treating patients with drug-resistant temporal lobe epilepsy, neurologists should screen diligently for emerging behavioral abnormalities and avolition. Similarly, psychiatrists must select antipsychotic agents that possess minimal seizure-threshold-lowering properties. For instance, second-generation antipsychotics such as aripiprazole or risperidone are generally favored over agents with higher proconvulsant risks like clozapine. Furthermore, addressing sleep deprivation, optimizing seizure control, and managing psychosocial stress mitigate postictal cascades. Therefore, routine implementation of standardized screening instruments, such as the Brief Psychiatric Rating Scale, bridges the gap between neurology and psychiatry clinics. Ultimately, early psychiatric diagnosis directly improves medical compliance, reduces emergency admissions, and preserves cognitive functionality in this complex patient demographic.

Diagnostic Workup and Therapeutic Strategies

A rigorous diagnostic evaluation remains critical to distinguish true psychotic comorbidity from medication toxicities or nonconvulsive status epilepticus. Clinicians should obtain continuous video-electroencephalography to evaluate whether acute psychotic symptoms represent subclinical ictal discharges. In addition, high-resolution magnetic resonance imaging helps identify hippocampal sclerosis, cortical dysplasias, or previous traumatic contusions. When managing acute postictal psychosis, clinicians frequently employ short courses of low-dose atypical antipsychotics or benzodiazepines to restore behavioral stability. However, the definitive prevention of postictal episodes relies on eliminating seizure clusters through aggressive antiepileptic optimization. For chronic interictal psychosis, providers should cautiously initiate low-dose antipsychotic maintenance while monitoring therapeutic drug levels and seizure frequency. Because sudden medication adjustments can destabilize neurological equilibrium, clinicians must balance seizure suppression against neurocognitive tolerability. Consequently, structured follow-up intervals and shared decision-making empower patients and families to navigate these challenging dual diagnoses effectively.

Frequently Asked Questions

What distinguishes postictal psychosis from interictal psychosis in clinical practice?

Postictal psychosis typically emerges after a distinct lucid interval of 12 to 72 hours following a seizure cluster and usually resolves within days or weeks. Conversely, interictal psychosis develops independently of acute seizure events, follows a chronic course, and persists during periods without active paroxysmal electrical discharges.

Why does perampanel therapy elevate the risk of psychiatric complications in epilepsy?

Perampanel acts as a selective non-competitive AMPA glutamate receptor antagonist in the central nervous system. Because AMPA receptors modulate emotional processing and frontolimbic circuits, blocking them can induce significant psychiatric adverse effects, including irritability, severe aggression, hostility, anxiety, and an increased risk of psychosis in vulnerable individuals.

How should clinicians approach antipsychotic selection in patients with active seizures?

Clinicians must choose atypical antipsychotics that carry a low risk of lowering the seizure threshold, such as aripiprazole, risperidone, or quetiapine. They should avoid highly proconvulsant agents like clozapine and chlorpromazine. In addition, providers should start at low doses and titrate gradually alongside stable antiepileptic drug therapy.

Disclaimer: This content is for informational and educational purposes only and should not be considered as medical advice. Healthcare professionals should make clinical decisions based on their independent judgment and individual patient assessments. Refer to the latest local and national guidelines for clinical practice.

References

1. Shen S et al. Prevalence, clinical characteristics, and risk factors for psychosis in people with epilepsy: A multicenter retrospective cohort study. Epilepsia. 2025 Aug. doi: 10.1111/epi.18409. PMID: 40266083.
2. MDPI Review. Psychosis of Epilepsy: An Update on Clinical Classification and Mechanism. Brain Sciences. 2025 Jan;15(1):45. doi: 10.3390/brainsci15010045.
3. Mula M. Epilepsy and psychosis: navigating through a complex intersection. Therapeutic Advances in Neurological Disorders. 2022;15:17562864221102245. doi: 10.1177/17562864221102245.
4. Kanner AM. Management of psychiatric comorbidities in epilepsy: an update. Journal of Clinical Neurology. 2023;19(2):121-133. doi: 10.3988/jcn.2023.19.2.121.